SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 323 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,011 | +5.9% | 140,329 | 0.0% | 0.23% | +12.1% |
| Q2 2023 | $16,070 | -16.9% | 140,329 | 0.0% | 0.21% | -21.9% |
| Q1 2023 | $19,342 | +24.1% | 140,329 | +16.6% | 0.26% | +28.0% |
| Q4 2022 | $15,592 | -99.9% | 120,329 | 0.0% | 0.21% | +13.1% |
| Q3 2022 | $13,301,000 | +47.5% | 120,329 | 0.0% | 0.18% | +61.9% |
| Q2 2022 | $9,020,000 | -4.0% | 120,329 | 0.0% | 0.11% | +10.8% |
| Q1 2022 | $9,400,000 | -13.3% | 120,329 | 0.0% | 0.10% | 0.0% |
| Q4 2021 | $10,836,000 | -2.6% | 120,329 | 0.0% | 0.10% | -10.5% |
| Q3 2021 | $11,128,000 | +19.0% | 120,329 | 0.0% | 0.11% | +18.8% |
| Q2 2021 | $9,354,000 | +4.3% | 120,329 | 0.0% | 0.10% | +9.1% |
| Q1 2021 | $8,968,000 | -56.3% | 120,329 | 0.0% | 0.09% | -57.3% |
| Q4 2020 | $20,515,000 | +0.5% | 120,329 | -17.2% | 0.21% | -10.4% |
| Q3 2020 | $20,409,000 | -12.4% | 145,329 | 0.0% | 0.23% | -15.4% |
| Q2 2020 | $23,302,000 | +63.9% | 145,329 | 0.0% | 0.27% | +37.4% |
| Q1 2020 | $14,216,000 | -24.2% | 145,329 | 0.0% | 0.20% | -11.6% |
| Q4 2019 | $18,753,000 | +71.3% | 145,329 | 0.0% | 0.22% | +61.2% |
| Q3 2019 | $10,946,000 | -37.5% | 145,329 | +26.0% | 0.14% | -36.2% |
| Q2 2019 | $17,524,000 | +480.5% | 115,329 | +355.3% | 0.22% | +473.7% |
| Q1 2019 | $3,019,000 | -20.9% | 25,329 | -27.6% | 0.04% | -30.9% |
| Q4 2018 | $3,816,000 | -49.8% | 34,968 | -25.7% | 0.06% | -43.9% |
| Q3 2018 | $7,598,000 | -17.2% | 47,046 | -32.2% | 0.10% | -22.8% |
| Q2 2018 | $9,177,000 | +84.1% | 69,427 | +3.2% | 0.13% | +64.9% |
| Q1 2018 | $4,984,000 | -10.9% | 67,272 | -33.0% | 0.08% | -4.9% |
| Q4 2017 | $5,591,000 | +0.6% | 100,478 | -18.0% | 0.08% | +2.5% |
| Q3 2017 | $5,555,000 | +35.6% | 122,469 | +0.8% | 0.08% | +27.4% |
| Q2 2017 | $4,097,000 | +67.3% | 121,528 | +46.9% | 0.06% | +51.2% |
| Q1 2017 | $2,449,000 | +2591.2% | 82,735 | +2404.1% | 0.04% | +1950.0% |
| Q4 2016 | $91,000 | – | 3,304 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |